Topic:

Venture Capital

Latest Headlines

Latest Headlines

'Painful' regulations keeping Google on the periphery of life sciences

Over the past few years, Google has expanded into life sciences, with venture capital investments, the creation of Calico and development of "smart" contact lenses giving it multiple beachheads in the industry. But the search giant's co-founders have reservations about getting deep into healthcare, saying regulations make it a "painful" sector in which to work.

Neuropsychiatric biotech raises $20M for PhII program

The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $6 million Series A from Morningside.

Biotech vets sign up to launch Cidara with $32M, new drugs for fungal infections

Cidara Therapeutics has emerged from stealth mode with a crew of experienced biotech execs, a $32 million bankroll from a slate of top-shelf venture investors and a plan to make a difference in developing frontline antifungal drugs.

J&J Innovation shows off its new summer lineup of biotech deals

Johnson & Johnson Innovation has announced a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers--all aimed at putting the multinational pharma giant on the cutting edge of new product development.

Navitor grabs a $23.5M A round to tackle a key crossroad for disease

A little more than a year ago, GlaxoSmithKline disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new biotech dubbed Navitor Pharmaceuticals, which was seeded initially by Polaris and is now coming out of stealth mode with a $23.5 million Series A and the backing of a syndicate that includes SR One, GlaxoSmithKline's venture arm.

True North snags $22M and sets course for the clinic with a rare disease drug

Two months removed from a deal that sent her last biotech to Bristol-Myers Squibb for up to $725 million, CEO Nancy Stagliano isn't wasting any time, setting sights on rare diseases with True North Therapeutics, her latest venture, and locking down a $22 million A round to move forward.

Seres bags another $10M to gut it out in microbiomics

Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.

Trevi, Complexa bag $38M in VC cash to hit the gas on R&D

Two biotech startups have hauled in a combined $38 million in Series B funding, pledging to advance their programs in inflammation and skin disease.

Sequoia raises $530M to invest in Indian tech and health startups

Having backed biotech IT businesses like Comprehend Systems and SV Bio in the U.S., high-profile venture firm Sequoia Capital has turned its attention to India. And with a $530 million fund to fuel its ambitions, the California-based VC shop could kick-start the tech and healthcare startup ecosystem in India and across Southeast Asia.

ARMO pockets $30M for its immunotherapy ahead of the ASCO spotlight

Armed with ex-Merck immunotherapy and some promising preclinical data, startup ARMO BioSciences has pulled in $30 million in venture cash to study whether its candidate can help kill cancer cells by galvanizing an immune system response.